2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- -10.01%1-Year Change
- BiotechnologyIndustry
Bav Nord Sp ADR (BVNRY)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 62
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram
Bavarian Nordic A/S has completed additional share repurchases under its DKK 250 million buy-back program initiated on September 1, 2026. Between September 21-25, the company purchased 57,000 shares at an average price of DKK 210.94, bringing total accumulated purchases to 459,322 shares (5.07% of share capital) worth DKK 96.89 million.
09/28/2026, 2:47 AM • GlobeNewswire
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic A/S announced progress on its share buy-back program launched September 1, 2026. Between September 21-25, 2026, the company repurchased 57,000 shares at an average price of DKK 210.94, bringing total accumulated repurchases to 459,322 shares worth DKK 96.9 million. The company now holds 4,017,913 treasury shares, representing 5.07% of share capital.
09/28/2026, 2:47 AM • GlobeNewswire
Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram
Bavarian Nordic A/S has completed transactions under its share buy-back program initiated on September 1, 2026, repurchasing 401,322 shares at an average price of DKK 210.19 per share, totaling DKK 84.35 million. The company now holds 3,959,913 treasury shares, representing 4.996% of its share capital. The program runs through October 30, 2026, with a total budget of DKK 250 million.
09/21/2026, 2:41 AM • GlobeNewswire
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic A/S has repurchased 401,322 shares under its DKK 250 million buy-back program launched September 1, 2026, with an average purchase price of DKK 210.19. The company now holds 3,959,913 treasury shares, representing 4.996% of share capital. The program runs through October 30, 2026.
09/21/2026, 2:41 AM • GlobeNewswire
Bavarian Nordic udnævner Tarja Stenvall til administrerende direktør
Bavarian Nordic A/S announced the appointment of Tarja Stenvall as new Chief Executive Officer effective October 15, 2026, replacing Paul Chaplin. Stenvall brings over 20 years of healthcare leadership experience from Sanofi, AstraZeneca, and Pfizer, with expertise in scaling global life science companies and vaccine development. The company positions itself as a leading global vaccine provider with a strong scientific foundation and commercial platform.
09/17/2026, 1:55 AM • GlobeNewswire
Tarja Stenvall Appointed Chief Executive Officer of Bavarian Nordic
Bavarian Nordic A/S announced the appointment of Tarja Stenvall as President and Chief Executive Officer, effective October 15, 2026, replacing Paul Chaplin. Stenvall brings over 20 years of global healthcare leadership experience from Sanofi, AstraZeneca, and Pfizer, with expertise in scaling vaccine and pharmaceutical businesses. The company positions itself as a leading global vaccine supplier with a strong foundation for future growth.
09/17/2026, 1:55 AM • GlobeNewswire
Bavarian Nordic reports insider transactions on September 3-4, 2026. Executive Vice President Russell Thirsk exercised warrants to subscribe for 28,590 shares at DKK 190.11 per share and immediately sold them at DKK 215.47 per share, realizing a profit of approximately DKK 725,277. Board member Anja Gjøl sold 345 shares at prices ranging from DKK 221.80 to DKK 222.00.
09/04/2026, 12:00 PM • GlobeNewswire
Bavarian Nordic A/S reports insider transactions by key executives. Russell Thirsk, Executive Vice President and Chief Operating Officer, exercised 28,590 warrants at DKK 190.11 per share and subsequently sold all 28,590 shares at DKK 215.47 per share on September 4, 2026. Board member Anja Gjøl sold 345 shares at prices ranging from DKK 221.80 to DKK 222.00 on September 3, 2026.
09/04/2026, 12:00 PM • GlobeNewswire
Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner
Bavarian Nordic A/S announced a capital increase of DKK 285,900 following employees' exercise of subscription options. The company issued 28,590 new shares at DKK 190.11 per share, generating DKK 5.4 million in proceeds. The total share capital is now DKK 792,653,180 distributed across 79,265,318 shares.
09/04/2026, 2:20 AM • GlobeNewswire
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
Bavarian Nordic A/S announced a share capital increase of DKK 285,900 resulting from employees exercising warrants. The company issued 28,590 new shares at DKK 190.11 per share, generating DKK 5.4 million in proceeds. The total share capital is now DKK 792,653,180 comprising 79,265,318 shares.
09/04/2026, 2:20 AM • GlobeNewswire
Bavarian Nordic lancerer første del af nyt aktietilbagekøbsprogram
Bavarian Nordic A/S has commenced the first phase of a DKK 750 million share buyback program on September 1, 2026, with the initial phase targeting DKK 250 million in repurchases. The program, authorized by the general meeting and compliant with EU market abuse regulations, will be managed by Nordea and is intended to optimize the company's capital structure through subsequent cancellation of repurchased shares.
09/01/2026, 1:30 AM • GlobeNewswire
Bavarian Nordic Launches First Tranche of New Share Buy-Back Program
Bavarian Nordic A/S has launched the first tranche of a DKK 750 million share buy-back program on September 1, 2026, with the initial tranche comprising up to DKK 250 million. The program aims to adjust the company's capital structure through subsequent cancellation of repurchased shares and will be completed by October 30, 2026, with a maximum of 4,365,000 shares to be repurchased.
09/01/2026, 1:30 AM • GlobeNewswire
Bavarian Nordic A/S reports insider transactions where CEO Paul Chaplin sold 90,000 shares at DKK 212.42 per share (DKK 19.1 million) on August 24, 2026, and Maria Tzatzaris, closely associated with Chaplin, sold 14,840 shares at DKK 207.91 per share (DKK 3.1 million) on August 21, 2026, both on Nasdaq Copenhagen.
08/25/2026, 3:00 PM • GlobeNewswire
Bavarian Nordic A/S reported insider transactions on August 24-25, 2026, with CEO Paul Chaplin selling 90,000 shares at DKK 212.42 and a related party Maria Tzataris selling 14,840 shares at DKK 207.91. The company announced strong first half 2026 results and plans a new share buy-back program of up to DKK 750 million.
08/25/2026, 3:00 PM • GlobeNewswire
Bavarian Nordics chikungunyavaccine indsendt til myndighedsgodkendelse i Brasilien
Bavarian Nordic announced that its partner Eurofarma has submitted a marketing authorization application to Brazil's health authority Anvisa for CHIKV VLP, a chikungunya vaccine for individuals 12 years and older. This milestone represents a significant step in expanding vaccine access to one of the countries most affected by chikungunya, where over half of global cases and deaths occur.
07/13/2026, 9:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/02/2026
Company Profile
BAVARIAN NORDIC R/I S/ADR
Key Executives
- Paul John Chaplin
- Henrik Juuel
- Nicole Seroff
- Jean-Christophe May
- Russell Thirsk
Current Ownership Distribution
- Other231.1M (99.85%)
- Mutual Funds336,146 (0.15%)
- Institutions0 (0.00%)
- Insiders0 (0.00%)